Drug sponsors will continue to streamline clinical trial protocols in the near term as part of an industrywide effort to improve R&D productivity, according to a new report.

Drug sponsors could experience greater certainty during drug reviews if the agency’s upcoming pilot program to standardize the evaluation of new products is a success.

The FDA is finishing a final guidance on co-development of two or more novel drugs for use in combination and hopes to release it in the next few months, Center for Drug Evaluation and Research Director Janet Woodcock tells CTA.